Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Inclusion Criteria

• •Men and women ≥ 18 years of age.
• •Part 1: A confirmed diagnosis of FL Grade 1, 2, or 3a, which has relapsed after, or been refractory to ≥ 1 prior therapy for FL, or subjects who have not previously received systemic anticancer therapy for FL., and which requires treatment.
• •Part 2: For subject with relapsed or refractory MZL:
• •Histologically confirmed MZL including splenic, nodal, and extranodal sub-types
• •1. Subjects with splenic MZL must have an additional measurable lesion, nodal or extranodal, as described in inclusion criterion #4;
• •2. Subjects with gastric mucosa-associated lymphoid tissue (MALT) lymphoma must be Helicobacter pylori (HP)-negative
• •* Part 3: For subjects with FL: Pathologically confirmed diagnosis of FL Grade 1, 2, or 3a, which has relapsed after, or been refractory to ≥ 1 prior therapy for FL and which requires treatment per National Cancer Institute or ESMO clinical practice guidelines.
• •* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
• •* Agreement to use contraception during the study and for 30 days after the last dose of study drugs if sexually active and able to bear or beget children.